ASPG and acute lymphoblastic leukemia: FDA approval for PEGylated asparaginase (Rhone-Poulenc Rorer as Oncaspar®) was granted in 1994 for the treatment of acute lymphoblastic leukemia (ALL) patients who are hypersensitive to the two native isoforms of the enzyme (Pasut and Veronese, 2009) (Table 3).